GSK PLC Sponsored ADR $GSK is Keystone Financial Planning Inc.’s 5th Largest Position

Keystone Financial Planning Inc. boosted its position in GSK PLC Sponsored ADR (NYSE:GSK) by 3,114.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 195,590 shares of the pharmaceutical company’s stock after purchasing an additional 189,506 shares during the period. GSK makes up about 2.6% of Keystone Financial Planning Inc.’s holdings, making the stock its 5th largest holding. Keystone Financial Planning Inc.’s holdings in GSK were worth $10,253,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. Fisher Asset Management LLC boosted its stake in shares of GSK by 3.0% during the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after purchasing an additional 968,370 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after buying an additional 852,437 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of GSK by 2,032.8% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock valued at $41,896,000 after buying an additional 814,275 shares during the last quarter. Waverly Advisors LLC raised its position in shares of GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after buying an additional 270,863 shares during the last quarter. Finally, Kahn Brothers Group Inc. purchased a new position in shares of GSK during the second quarter valued at approximately $8,305,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of GSK in a research report on Tuesday. They set a “sector perform” rating on the stock. Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Citigroup initiated coverage on GSK in a research note on Friday, July 24th. They set a “neutral” rating on the stock. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, HSBC raised GSK from a “reduce” rating to a “hold” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $53.00.

GSK Price Performance

GSK stock opened at $48.66 on Thursday. GSK PLC Sponsored ADR has a 1 year low of $39.29 and a 1 year high of $61.69. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The firm has a 50 day moving average price of $51.51 and a 200 day moving average price of $52.91. The company has a market cap of $98.42 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 2.03 and a beta of 0.35.

GSK (NYSE:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. GSK’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts predict that GSK PLC Sponsored ADR will post 4.81 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a $0.4515 dividend. This is an increase from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.7%. GSK’s dividend payout ratio is 55.63%.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.